How we make this list: we compare pricing pages, product documentation and public user reviews. Ratings come from G2, Capterra or Trustpilot, with the date we checked them.
Key takeaways
- This article ranks medical device companies by revenue and focus, not products you buy directly, and it is general information only, not investment or medical advice.
- Medtronic leads the 2026 rankings at $36.4 billion in annual revenue, with strength in cardiovascular, neuroscience, surgical, and diabetes devices.
- Johnson and Johnson MedTech follows at $33.8 billion, with orthopaedics, surgery, and interventional solutions as its core segments.
- Siemens Healthineers and GE HealthCare lead in imaging, while Stryker and Boston Scientific lead in orthopaedics and cardiology respectively, so the right leader depends on the specialty.
Quick comparison
Is your product missing or out of date?
We review this list regularly. Vendors can request a listing, send updated pricing or ask about featured placement.
The best medical device companies
Starting priceSee website
Free planNo
Medtronic remains the largest medical device company in the 2026 rankings, with $36.4 billion in annual revenue reported in the Medtech Big 100. Its portfolio spans cardiovascular devices, neuroscience products including neuromodulation and cranial technologies, medical surgical tools, and diabetes care, with operations centered in Minneapolis and a legal domicile in Ireland. That breadth makes it the default comparison point for any hospital system buying across specialties.
The breadth is also the weakness. A company this large moves slowly on partnerships, and its diabetes division competes against focused rivals like Abbott and Dexcom in continuous glucose monitoring. Hospitals that want a single vendor across many departments will still find Medtronic the most complete option, while specialty buyers may prefer a focused leader below.
What we like- Largest revenue at $36.4 billion
- Strength across cardiac, neuro, surgical, and diabetes
- Presence in 150 plus countries
Watch out for- Scale brings slower decision-making
- Diabetes business faces intense competition
#2
Johnson and Johnson MedTech
Best for: Orthopaedics and surgery
Visit jnj.com
Starting priceSee website
Free planNo
Johnson and Johnson MedTech, based in New Brunswick, New Jersey, reported $33.8 billion in MedTech revenue in 2025, ranking second in the 2026 lists. Its core segments are orthopaedics through DePuy Synthes, surgery including Ethicon sutures and staplers, interventional solutions, and vision care. The parent company's scale gives MedTech deep research funding and a global sales force few rivals can match.
MedTech priorities can shift inside a parent company that also sells pharmaceuticals and consumer health products, which is a governance risk for partners betting on a single segment. Orthopaedics also faces hospital pricing pressure as systems consolidate purchasing. For surgery and orthopaedics buyers, Johnson and Johnson MedTech remains one of the two or three vendors that must be evaluated.
What we like- $33.8 billion MedTech revenue
- Strong orthopaedics and surgery brands
- Global reach in 175 plus countries
Watch out for- MedTech is one segment of a much larger company
- Orthopaedics faces pricing pressure
Starting priceSee website
Free planNo
Siemens Healthineers, headquartered in Erlangen, Germany, reported about 23.4 billion euros in fiscal 2025 revenue, roughly $26.9 billion, ranking among the top four medtech companies. Its strengths are advanced imaging including MRI, CT, and molecular imaging, laboratory diagnostics, and AI-powered radiology tools, plus radiotherapy through Varian. Hospitals building a new imaging center almost always evaluate Healthineers against GE HealthCare.
Premium pricing on high-end scanners is the main drawback, and a European headquarters can complicate procurement for US systems that prefer domestic vendors. Service networks in the United States are extensive, though, and AI integration in imaging is a genuine differentiator. For imaging-led purchases, Healthineers is the benchmark.
What we like- About $26.9 billion revenue
- Imaging and AI radiology leadership
- Diagnostics plus radiotherapy
Watch out for- European headquarters adds procurement complexity for some US buyers
- Premium pricing on high-end imaging
Starting priceSee website
Free planNo
Stryker, based in Kalamazoo, Michigan, reported $25.1 billion in 2025 revenue, with orthopaedic implants, MedSurg equipment, and neurotechnology as its pillars. Its Mako robotic-arm system for joint replacement is one of the most widely adopted surgical robots in orthopaedics, and its emergency care and surgical equipment lines give hospitals a second reason to standardize on Stryker.
Concentration in orthopaedics means elective surgery volumes drive results, so downturns in joint replacement hit Stryker harder than diversified rivals. Mako systems also carry high capital costs plus per-procedure disposables, which hospitals must model carefully. For orthopaedic programs, Stryker is the leader most surgeons request by name.
What we like- $25.1 billion revenue
- Orthopaedic implants plus Mako robotics
- Strong MedSurg and neurotechnology lines
Watch out for- Orthopaedics concentration creates cyclical exposure
- Robotics systems carry high capital cost
Starting priceSee website
Free planNo
Abbott Laboratories, based in Abbott Park, Illinois, reported a medical device segment of about $21.4 billion in the 2026 rankings, with diabetes care, cardiovascular devices, and neuromodulation as its core device lines. Its FreeStyle Libre continuous glucose monitoring system is the best-known product in diabetes care, and its cardiovascular portfolio spans structural heart, electrophysiology, and vascular devices.
As with Johnson and Johnson, device priorities compete with diagnostics, nutrition, and pharmaceuticals inside the parent company, though Abbott device growth has outpaced several segments. Diagnostics competition from Danaher and Siemens is intense. For diabetes care and cardiology buyers, Abbott is the vendor most likely to appear on every shortlist.
What we like- Medical device segment about $21.4 billion
- FreeStyle Libre leadership
- Cardiovascular depth
Watch out for- Device revenue sits inside a larger diversified company
- Diagnostics competition is intense
Starting priceSee website
Free planNo
GE HealthCare, headquartered in Chicago, reported $20.6 billion in 2025 revenue, with imaging including MRI, CT, PET, and ultrasound, plus patient monitoring and AI diagnostics as its core lines. Its installed base in US hospitals is enormous, which makes service coverage and parts availability a practical advantage over smaller imaging vendors.
The company spun off from General Electric in 2023 and is still building its standalone identity, though its product lines are mature. High-end imaging systems carry significant service costs, so total cost of ownership matters more than the purchase price. For hospitals standardizing imaging and monitoring together, GE HealthCare is the natural rival to Siemens Healthineers.
What we like- $20.6 billion revenue
- Imaging breadth from MRI to ultrasound
- AI diagnostics expansion
Watch out for- Spun off from GE in 2023, still building standalone identity
- Service costs on high-end systems
Starting priceSee website
Free planNo
Boston Scientific, based in Marlborough, Massachusetts, reported $20.1 billion in 2025 revenue, with the fastest growth rate among the largest companies in several 2026 guides. Its strengths are interventional cardiology, electrophysiology, endoscopy, urology, and neuromodulation, with structural heart and electrophysiology portfolios driving recent growth.
The portfolio is narrower than Medtronic or Johnson and Johnson, so Boston Scientific suits specialty buyers more than hospitals seeking one vendor for everything. Growth also depends on continued acquisitions and regulatory approvals, which adds risk. For cardiology and endoscopy programs, Boston Scientific is the growth leader and a must-evaluate vendor.
What we like- $20.1 billion revenue
- Fastest growth among leaders
- Cardiology, endoscopy, and urology depth
Watch out for- Narrower portfolio than Medtronic
- Growth depends on acquisitions and new approvals
#8
BD
Best for: Medication delivery and diagnostics
Visit bd.com
Starting priceSee website
Free planNo
BD, or Becton, Dickinson and Company, based in Franklin Lakes, New Jersey, reported medical and interventional segment revenue of about $18.5 billion in the 2026 rankings. Its strengths are medication delivery systems including syringes and infusion devices, specimen management, diagnostics, and infection prevention, with a presence in 190 countries that few rivals match.
Consumables face commodity pricing pressure, so BD margins depend on volume and automation rather than breakthrough devices. Its interventional segment adds higher-value products, but BD will never be the robotics or imaging leader. For hospitals buying medication delivery and diagnostics at scale, BD is the volume backbone of the supply chain.
What we like- Medical and interventional segments about $18.5 billion
- Unmatched consumables scale
- Presence in 190 countries
Watch out for- Consumables focus means less high-tech device glamour
- Pricing pressure on commodity products
How we chose
We compared 2026 ranking guides including the Medtech Big 100 and revenue-based lists, checking reported revenue, headquarters, and primary segments for each company. We favored companies with clearly reported medical device revenue and a distinct specialty strength, and we noted where guides disagree on segment figures, since companies report segments differently. Revenue figures are guide figures from published rankings, not audited statements quoted here. We did not claim hands-on testing, and this article is general information only, not investment or medical advice.
Reading the rankings correctly
Revenue rank is not a quality rank. A hospital buying an MRI scanner should compare Siemens Healthineers and GE HealthCare, not pick Medtronic because it is largest overall. A cardiology program should compare Boston Scientific, Abbott, and Medtronic on the specific procedure, while an orthopaedic program should compare Stryker, Johnson and Johnson, and Zimmer Biomet. Use this list to build a shortlist by specialty, then evaluate devices on clinical evidence, service terms, and total cost.
Growth versus scale
Boston Scientific and Stryker show the fastest growth among the leaders, which often signals strong new product pipelines, but growth can also reflect acquisitions that take time to integrate. Medtronic and Johnson and Johnson offer stability and breadth, which matters for multi-year standardization contracts. Balance the two: a fast-growing specialist can bring innovation, while a large diversified vendor brings staying power if a product line is discontinued.
What buyers should verify
Confirm FDA clearance status for the specific device model, not just the company, since clearance varies by indication. Check service coverage in your region, parts availability, and training terms, since a device without local service support becomes a liability. For capital equipment, model total cost including disposables, service contracts, and room preparation, not just the purchase price, and ask for references from hospitals of similar size.
Frequently asked questions
Who is the largest medical device company in 2026?
Medtronic ranks first in the 2026 Medtech Big 100 with $36.4 billion in annual revenue, followed by Johnson and Johnson MedTech at $33.8 billion and Siemens Healthineers at about $26.9 billion. Rankings vary slightly by source because companies report segments differently.
Which medical device company leads in diabetes care?
Abbott leads in continuous glucose monitoring with its FreeStyle Libre system, while Medtronic and Dexcom are the other major players. The right choice depends on the patient population, sensor accuracy needs, and whether insulin pump integration matters.
Are these companies good investments?
This article does not give investment advice. Medical device stocks move on regulatory approvals, reimbursement decisions, and procedure volumes, so investors should review company filings and consult a licensed financial adviser before acting on any ranking.
Which company makes the best surgical robot?
Intuitive Surgical leads robotic-assisted surgery overall with its da Vinci systems, while Stryker leads in orthopaedic robotics with Mako. The best system depends on the surgical specialty, since robots are designed for specific procedures rather than general surgery.
How do hospitals choose between these companies?
Hospitals evaluate clinical evidence, total cost of ownership, service coverage, and surgeon preference, usually through a value analysis committee. Standardization across a system can cut costs, but it must not override clinical outcomes for a specific procedure.
Sources we checked (10)
- https://www.medtronic.com
- https://www.jnj.com
- https://www.siemens-healthineers.com
- https://www.stryker.com
- https://www.abbott.com
- https://www.gehealthcare.com
- https://www.bostonscientific.com
- https://www.bd.com
- https://www.massdevice.com/largest-medical-device-companies-2026/
- https://healthcarereaders.com/news/top-medical-device-companies-by-revenue
Is your product missing or out of date?
We review this list regularly. Vendors can request a listing, send updated pricing or ask about featured placement.
Shihab Mia · Founder, Rankite
Shihab has 5+ years in B2B and SaaS SEO. He writes Rankite's software buying guides from pricing pages, documentation and public user reviews. More about Shihab.
Medtronic
Siemens Healthineers
Stryker
Abbott
GE HealthCare
Boston Scientific